Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-137235

Published: 2020

Journal Articles

Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score

Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Jason Valent, MD, Alex V. Mejia Garcia, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Nathaniel Rosko, PharmD, Christy J. Samaras, DO, Matt Kalaycio, MD, Faiz Anwer, MD, Alok A Khorana, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137525

Published: 2020

Journal Articles

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Nathaniel Rosko, PharmD, Hanjie Mo, PharmD, Joslyn Rudoni, PharmD, Caitlin Siebenaller, PharmD, Sarah S Lee, MD, Rajshekar Chakraborty, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Alex V. Mejia Garcia, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 1838.

https://doi.org/10.1182/blood-2019-124775

Published: 2019

Journal Articles

Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma

Rajshekar Chakraborty, MD, Lisa Rybicki, MS, Megan Nakashima, MD, Robert M. Dean, MD, Beth M. Faiman, PhDCNP, Christy J. Samaras, DO, Nathaniel Rosko, PharmD, Jason Valent, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 4359.

https://doi.org/10.1182/blood-2019-123861

Published: 2019

Journal Articles

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

Diana Basali, MD, Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Nathaniel Rosko, PharmD, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Hayley Dysert, Beth M. Faiman, PhDCNP, Kimberly Hamilton, APRN/PA, Matt Kalaycio, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 5566.

https://doi.org/10.1182/blood-2019-129002

Published: 2019

Journal Articles

External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients

Fahrettin Covut, MD, Ramsha Ahmed, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Alex V. Mejia Garcia, MD, Dana E Angelini, MD, Beth M. Faiman, PhDCNP, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Saveta Mathur, CNP, Kimberly Hamilton, APRN/PA, Nathaniel Rosko, PharmD, Jason Valent, MD, Jack Khouri, MD

Blood (2019) 134 (Supplement_1): 3148.

https://doi.org/10.1182/blood-2019-131400

Published: 2019

Journal Articles

Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis

Sarah S Lee, MD, Nathaniel Rosko, PharmD, Bhumika J. Patel, MD, Madeline Waldron, PharmD, Jackie Tomer, MPH, Roman Goldman, CNP, Mary Ann Karam, RN, Janice Reed, RN, Beth M. Faiman, PhDCNP, Kimberly Hamilton, APRN/PA, Saveta Mathur, CNP, Christy J. Samaras, DO, Jason Valent, MD

Blood (2018) 132 (Supplement 1): 2009.

https://doi.org/10.1182/blood-2018-99-119979

Published: 2018

Journal Articles

Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma

Rajshekhar Chakraborty, MBBS, Hien D. Liu, MD, Lisa Rybicki, MS, Robert M. Dean, MD, Beth M. Faiman, PhDCNP, Matt Kalaycio, MD, Jack Khouri, MD, Christy J. Samaras, DO, Navneet S. Majhail, MD MS, Jason Valent, MD

Blood (2018) 132 (Supplement 1): 1899.

https://doi.org/10.1182/blood-2018-99-113114

Published: 2018

Journal Articles

Daratumumab Is Safe and Highly Effective in AL Amyloidosis

Jack Khouri, MD, Thapa Bicky, MD, Frederic J. Reu, MD, Christy J. Samaras, DO, Hien D. Liu, MD, Mary Ann Karam, RN, Janice Reed, RN, Beth M. Faiman, PhDCNP, Jason Valent, MD

Blood (2017) 130 (Supplement 1): 1819.

https://doi.org/10.1182/blood.V130.Suppl_1.1819.1819

Published: 2017

NARROW

Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients

Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis

Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma

Daratumumab Is Safe and Highly Effective in AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only